What is Novavax's EPS (diluted)?

Novavax (NVAX) reported EPS (diluted) of -$0.06 in Q1 2026.

How has Novavax's EPS (diluted) changed year-over-year?

Novavax's EPS (diluted) decreased by 102.0% year-over-year, from $2.93 to -$0.06.

What is the long-term trend for Novavax's EPS (diluted)?

Over 4 years (2021 to 2025), Novavax's EPS (diluted) has grown at a -43.7% compound annual growth rate (CAGR), from -$23.42 to $2.35.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Novavax NVAX EPS (Diluted)

EPS (Diluted) at other companies

ModernaMRNA

-$3.40-34.9%

Merck & Co.MRK

-$1.72-186%

Vaxcyte, Inc.PCVX

-$2.30-121%

Viridian Therapeutics, Inc.VRDN

-$1.15-5.5%

ALN

Alnylam PharmaceuticalsALNY

$1.51+1,179%

Gilead SciencesGILD

$1.61+54.8%

Other financials

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

Balance sheet

See full

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

See full

Market cap$1.46B+28.6%

Enterprise value$1.53B+68.6%

P/S2.5×+1.5×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's EPS (diluted)?: Novavax (NVAX) reported EPS (diluted) of -$0.06 in Q1 2026.
How has Novavax's EPS (diluted) changed year-over-year?: Novavax's EPS (diluted) decreased by 102.0% year-over-year, from $2.93 to -$0.06.
What is the long-term trend for Novavax's EPS (diluted)?: Over 4 years (2021 to 2025), Novavax's EPS (diluted) has grown at a -43.7% compound annual growth rate (CAGR), from -$23.42 to $2.35.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.